EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: Tradition or Innovation?

Domenico Laviola iD, Giovanna Manzi iD, Tommaso Recchioni iD, Maria Cristina Luise, Valentina Mercurio, Alexandra Mihai, Roberto Badagliacca iD, Silvia Papa iD, Carmine Dario Vizza iD

Journal of Cardiovascular Development and Disease · 16.07.2025 · 12 (7) · 271

DOI: 10.3390/jcdd12070271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 16.07.2025. Verfasst von Domenico Laviola und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic thromboembolic pulmonary hypertension (CTEPH) can complicate the clinical course of patients with acute pulmonary embolism, with a variable prevalence of 0.5–4%. Beyond specific therapeutic strategies, including pulmonary endarterectomy, balloon pulmonary angioplasty and pulmonary vasodilators, lifelong anticoagulation still represents the mainstay of treatment for this condition. The main historical experience supports the use of vitamin K antagonists (VKAs) in CTEPH patients; conversely, the efficacy and safety of direct oral anticoagulants (DOACs) in this setting are unclear. Growing experience, mainly from small studies and registries, is improving our knowledge, showing that DOACs may represent a valid and promising alternative to warfarin in CTEPH patients. Therefore, in the management of cases with a newly diagnosed CTEPH, clinicians are very often in the difficult position of (a) having to choose which anticoagulant to initiate in anticoagulant-naïve patients or (b) having to evaluate whether it is necessary to switch to a VKA in patients already on DOACs. This article aims to critically summarize the current evidence comparing DOACs and VKAs in CTEPH, discussing their efficacy and safety profiles and exploring their clinical applicability.

Schlagwörter

Stichwörter der Autor:innen

DOACschronic thromboembolic pulmonary hypertensiondirect oral anticoagulants

Autor:innen und Institutionen

  • Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Policlinico Universitario Umberto I, Sapienza University of Rome, 00161 Rome, Italy.
  • Department of Translational Medical Sciences, Federico II University of Naples, 80138 Naples, Italy.

ORCID-Profile: Domenico Laviola, Giovanna Manzi, Tommaso Recchioni, Roberto Badagliacca, Silvia Papa, Carmine Dario Vizza

Zitieren

APA

Laviola, D., Manzi, G., Recchioni, T., Luise, M. C., Mercurio, V., Mihai, A., Badagliacca, R., Papa, S., & Vizza, C. D. (2025). Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: Tradition or Innovation?. Journal of Cardiovascular Development and Disease, 12(7), 271. https://doi.org/10.3390/jcdd12070271

Vancouver

Laviola D, Manzi G, Recchioni T, Luise MC, Mercurio V, Mihai A, et al. Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: Tradition or Innovation?. Journal of Cardiovascular Development and Disease. 2025;12(7):271. doi:10.3390/jcdd12070271

BibTeX
@article{Laviola2025,
  author = {Laviola, Domenico and Manzi, Giovanna and Recchioni, Tommaso and Luise, Maria Cristina and Mercurio, Valentina and Mihai, Alexandra and Badagliacca, Roberto and Papa, Silvia and Vizza, Carmine Dario},
  title = {Oral Anticoagulants in Chronic Thromboembolic Pulmonary Hypertension: Tradition or Innovation?},
  journal = {Journal of Cardiovascular Development and Disease},
  year = {2025},
  volume = {12},
  number = {7},
  pages = {271},
  doi = {10.3390/jcdd12070271}
}
Kostenlos starten →